Aptus Pharma Board Approves Plan To Raise ₹44.88 Crore Via Equity Shares

Market snapshot: Aptus Pharma Limited's Board of Directors has approved a major capital infusion plan to raise ₹44.88 crore. The company intends to issue 16,02,870 equity shares on a preferential basis to 190 selected investors at an issue price of ₹280 per share. This substantial fundraising matches its long-term strategic plans of establishing manufacturing capacity, pursuing pan-India expansion, and building international market presence.

Data Snapshot

• Board approved proposed preferential issue of 16,02,870 equity shares at ₹280 each, amounting to ₹44.88 crore, to 190 investors.
• Revenue from operations for the financial year ended March 31, 2026 rose by 89.7% year-on-year to ₹46.57 crore from ₹24.56 crore.
• Net profit after tax for the financial year 2026 rose 49.0% year-on-year to ₹4.62 crore compared to ₹3.10 crore in the previous year.

What's Changed

• Operational revenue nearly doubled in the latest fiscal year, growing to ₹46.57 crore compared to ₹24.56 crore in the previous year.
• The company finalized a 3:2 bonus equity share issue in May 2026, allotting 1,02,90,000 fully paid bonus shares and adjusting its market lot size.
• Equity capital base is set to expand by 1.60 million shares post the upcoming annual general meeting on September 14, 2026.

Key Takeaways

• Aptus Pharma's board approved a ₹44.88 crore preferential allotment consisting of 16.03 lakh equity shares at ₹280 per share.
• The issue will be distributed to 190 designated public and corporate investors, increasing their post-issue holdings to 4.50%.
• Strategic proceeds are intended to fund manufacturing expansion, pan-India distribution growth, and international market outreach.
• Strong top-line performance is backed by a diversified portfolio of over 250 formulations, though operating margin compressed from 19.7% to 16.0% in the latest fiscal year.

SAHI Perspective

The planned fundraise of ₹44.88 crore is highly significant for Aptus Pharma, representing close to double its current net worth of ₹23 crore and approximately 63% of its trailing twelve-month revenue. Transitioning from a pure contract-manufacturing, asset-light model to owning manufacturing capabilities and broadening distribution could significantly alter the company's margin profile. However, while top-line expansion remains robust with nearly 90% revenue growth, the operational margin compression indicates high costs of customer acquisition and geographical scaling. Investors should closely watch how effectively this fresh capital is deployed into high-yield assets.

Market Implications

The massive capital injection strengthens the balance sheet, dramatically reduces leverage, and enhances liquidity for expanding product lines such as life-saving injectables, ICU care, and the newly launched urology segment. This is likely to support positive market sentiment around the stock in the short term, though the incoming shares will dilute existing non-participating shareholders.

Trading Signals

Market Bias: Bullish

The proposed capital infusion of ₹44.88 crore strengthens liquidity, bolstering the company's financial base by approximately 195% of its net worth. Combined with stellar top-line growth of 89.7% in operational revenues for the latest fiscal year, the market is expected to react favorably to the expansion plans.

Overweight: Pharmaceuticals, SME Healthcare

Trigger Factors:

• Shareholder approval of the preferential allotment at the Annual General Meeting on September 14, 2026.
• Successful deployment of funds toward manufacturing facilities.
• Quarterly margin trajectory improvements from the compressed 16.0% levels.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian pharmaceutical formulations and OTC wellness sectors are witnessing steady demand, with SME players aggressively scaling through franchise models and niche therapeutic entries. Aptus Pharma's recent expansion into the urology therapy segment and ICU care aligns with this high-margin trend, though geographical penetration across the highly fragmented national market demands intense capital commitment.

Key Risks to Watch

• Equity Dilution: The issuance of 1.60 million new shares will dilute the holdings of existing minority shareholders.
• Execution Risks: Transitioning from an asset-light, third-party manufacturing model to owned manufacturing structures involves high execution risks and capital expenditure gestation periods.
• Margin Pressure: Continued operating expense escalation and investments in sales-force expansion could further pressure profit margins.

Recent Developments

In May 2026, Aptus Pharma completed a 3:2 bonus equity share issue, allotting 1.03 crore fully paid bonus shares. Prior to this, in June 2026, the board approved an initial fundraising outline of up to ₹51 crore, which has now been structured with this ₹44.88 crore preferential issue. The company also expanded its therapy offerings by entering the urology and ICU care segments.

Closing Insight

While the ₹44.88 crore fundraise marks a pivotal scaling phase for Aptus Pharma, the transition to owned manufacturing and national markets will test management's execution efficiency. Maintaining high growth momentum without further hurting operating margins is critical to unlocking long-term shareholder value.

High Performance Trading with SAHI.